

Special Issue

Predicting Psychopathological Onset: Early Signs of Neuropsychiatric Diseases

Message from the Guest Editor

Millions of people worldwide are affected by neuropsychiatric disorders, such as anxiety, major depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder, and post-traumatic stress disorder. Although clinical tools are valuable in treating psychopathologies, the identification of early signs of psychopathology remains a main target to be reached in order to improve treatment effectiveness and reduce poor outcomes. The assessment of biological, behavioural, and cognitive markers of psychopathology could provide a significant support in pre-clinical phases to identify vulnerability factors, understand the course of illness and predict its outcome, as well as aid clinicians in the therapeutic decision-making process. In this Special Issue of the *Journal of Personalized Medicine*, papers addressing early markers of psychopathology aimed at improving diagnostic tools and at envisaging personalized therapies are welcome.

Guest Editor

Dr. Marco Costanzi

Department of Human Sciences, Lumsa University, 00100 Rome, Italy

Deadline for manuscript submissions

closed (10 December 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/47775

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).